/SYGGF
SYGGF Stock - Synairgen plc
Healthcare|BiotechnologyOTC
$0.00+0.00%
+$0.00 (+0.00%) • Dec 19
39
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.22
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SYGGF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.00 – $0.00
TARGET (TP)$0.00
STOP LOSS$0.00
RISK/REWARD1:-1.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.44
52W High$0.04
52W Low$0.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | $-84,000 | $-102,000 | $-195,000 | $-260,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-8,324,000 | $-10,292,000 | $-20,300,000 | $-57,866,000 | $-17,741,000 |
| Net Income | $-6,811,000 | $-8,408,000 | $-17,645,000 | $-48,663,000 | $-13,916,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.03 | $-0.04 | $-0.09 | $-0.24 | $-0.09 |
Company Overview
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease; and LOXL2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) disease. The company has a licensing and collaboration agreement with Pharmaxis Ltd. to develop a LOXL2 inhibitor. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
SYGGFBeat Rate
0%
Last 1 quarters
Avg Surprise
-9.9%
EPS vs Estimate
Beats / Misses
0/1
Last 12 quarters
Latest EPS
$-0.02
Q3 2024
EPS Surprise History
Q4 20
No data
Q2 21
No data
Q4 21
No data
Q2 22
No data
Q4 22
No data
Q2 23
-9.9%
$-0.03vs$-0.03
Q2 24
No data
Q3 24
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2025 | Jun 30, 2025 | — | — | — | — |
Q3 2024 | Sep 26, 2024 | — | $-0.02 | — | — |
Q2 2024 | Jun 27, 2024 | — | $-0.02 | — | — |
Q2 2023 | Jun 30, 2023 | $-0.03 | $-0.03 | -9.9% | ✗ MISS |
Q4 2022 | Dec 31, 2022 | — | $-0.03 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.07 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.11 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.23 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.09 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.04 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-0.02 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-0.02 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-0.00 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-0.00 | — | — |
Q4 2017 | Dec 31, 2017 | — | $0.00 | — | — |
Q2 2017 | Jun 30, 2017 | — | $-0.00 | — | — |
Q4 2016 | Dec 31, 2016 | — | $-0.00 | — | — |
Q2 2016 | Jun 30, 2016 | — | $-0.00 | — | — |
Q4 2015 | Dec 31, 2015 | — | $-0.00 | — | — |
Q2 2015 | Jun 30, 2015 | — | $-0.00 | — | — |
Latest News
Loading news...
Frequently Asked Questions about SYGGF
What is SYGGF's current stock price?
Synairgen plc (SYGGF) is currently trading at $0.00 per share. The stock has moved +0.00% today.
What is the analyst price target for SYGGF?
No analyst price targets are currently available for this stock.
What sector is Synairgen plc in?
Synairgen plc operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is SYGGF's market cap?
Synairgen plc has a market capitalization of $0.00 billion, making it a small-cap company.
Does SYGGF pay dividends?
No, Synairgen plc does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACMSY
AccuStem Sciences Limited
$0.13
0CLCS
Cell Source, Inc.
$0.50
Mkt Cap: $0.0B
GLABF
Gemina Laboratories Ltd.
$0.09
Mkt Cap: $0.0B
IMMVF
Immunovia AB (publ)
$0.05
Mkt Cap: $0.0B
IMUC
EOM Pharmaceuticals Holdings, Inc.
$0.15
Mkt Cap: $0.0B
PPCB
Propanc Biopharma, Inc.
$0.71
Mkt Cap: $0.0B
QPTFF
Quest PharmaTech Inc.
$0.01
Mkt Cap: $0.0B
SRBCF
Sirona Biochem Corp.
$0.01
Mkt Cap: $0.0B
TELIF
Telescope Innovations Corp.
$0.25
Mkt Cap: $0.0B
ZHCLF
Zenith Capital Corp.
$0.00
Mkt Cap: $0.0B
Explore stocks similar to SYGGF for comparison